Drugs / tesidolumab
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02878616 | Aug 2016 → Jul 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01255462 | Nov 2010 → Sep 2011 | age-related macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT02763644 | Apr 2016 → Feb 2017 | thrombotic microangiopathy | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02515942 | Sep 2015 → Aug 2017 | diffuse secondary choroid atrophy | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT02534909 | Sep 2015 → May 2022 | paroxysmal nocturnal hemoglobinuria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01526889 | Dec 2012 → Feb 2017 | intermediate uveitis, panuveitis, posterior uveitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01624636 | Dec 2012 → May 2013 | wet macular degeneration | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01535950 | Feb 2012 → Jul 2013 | wet macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01527500 | Jan 2012 → Jun 2015 | age-related macular degeneration, diffuse secondary choroid atrophy | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tesidolumab | “the human anti-C5 monoclonal antibody tesidolumab (LFG316)” PMID 32301258 ↗ May 2020 |
| Known as | LFG316 | “the human anti-C5 monoclonal antibody tesidolumab (LFG316)” PMID 32301258 ↗ May 2020 |
| Known as | NOV-4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298012 ↗ |
| Action | Inhibit | “a monoclonal antibody inhibitor of complement factor 5 (C5)” NCT02763644 ↗ |
| Modality | Monoclonal antibody | “an Anti-C5 Monoclonal Antibody” NCT02534909 ↗ |
| Route | Intravitreal | “intravitreal LFG316” NCT01255462 ↗ |
| Target | C5 | “an Anti-C5 Monoclonal Antibody” NCT02534909 ↗ |